Skip to main content
Fig. 1 | BMC Rheumatology

Fig. 1

From: Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Fig. 1

Proportions of guselkumab-randomized patients achieving MDA domain criteria (NRI) at weeks 24, 52, and 100. (a) MDA; (b) SJC ≤ 1; (c) TJC ≤ 1; (d) PASI score ≤ 1 among patients with PASI > 1 at baseline; (e) Patient pain (Pt Pain) score ≤ 15 mm among patients with Pt Pain > 15 at baseline; (f) Patient Global Assessment (PtGA) score ≤ 20 mm among patients with PtGA > 20 mm at baseline; (g) HAQ-DI score ≤ 0.5 among patients with HAQ-DI > 0.5 at baseline; (h) LEI ≤ 1 among patients with > 1 tender entheses at baseline. HAQ-DI = Health Assessment Questionnaire-Disability Index; LEI = Leeds enthesitis index; MDA = minimal disease activity; NRI = non-responder imputation; PASI = Psoriasis Area Severity Index; SJC = swollen joint count; TJC = tender joint count

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us